CureVac (NASDAQ:CVAC) Shares Purchased by Northern Trust Corp

Northern Trust Corp raised its position in CureVac (NASDAQ:CVAC) by 98.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,100 shares of the company’s stock after acquiring an additional 29,759 shares during the quarter. Northern Trust Corp’s holdings in CureVac were worth $205,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its stake in shares of CureVac by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock valued at $162,000 after purchasing an additional 4,425 shares during the period. Signaturefd LLC lifted its holdings in CureVac by 29.2% during the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company’s stock worth $123,000 after buying an additional 8,170 shares in the last quarter. XTX Topco Ltd boosted its position in CureVac by 90.2% in the 4th quarter. XTX Topco Ltd now owns 24,365 shares of the company’s stock valued at $83,000 after buying an additional 11,553 shares during the period. Barclays PLC boosted its position in CureVac by 51.8% in the 4th quarter. Barclays PLC now owns 34,836 shares of the company’s stock valued at $118,000 after buying an additional 11,890 shares during the period. Finally, Jump Financial LLC acquired a new position in shares of CureVac in the fourth quarter worth $55,000. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Stock Up 3.6%

Shares of NASDAQ:CVAC opened at $4.63 on Tuesday. CureVac has a fifty-two week low of $2.37 and a fifty-two week high of $5.28. The firm’s 50 day moving average price is $3.42 and its 200 day moving average price is $3.36. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of 8.42 and a beta of 2.43.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The firm had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $4.27 million. As a group, equities research analysts predict that CureVac will post 0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

CVAC has been the topic of several analyst reports. UBS Group reduced their price objective on CureVac from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. JMP Securities restated a “market outperform” rating and set a $10.00 price target on shares of CureVac in a report on Wednesday, May 28th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.